Optical Coherence Tomography -A New Monitoring Tool for Multiple Sclerosis?
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS) with inflammatory demyelinating lesions and neuronal loss that is clinically characterised by unpredictable clinical relapses, remissions and progression of disability over time. another. More recently, our attention has been focused on the nonphysical symptoms such as fatigue and cognitive symptoms.
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Despite significant advances in treatment, MS remains a highly disabling disease, and in many cases significantly reduces life expectancy.
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Recent studies have shown that initiating treatment early with a disease-modifying drug, possibly during CIS, can provide significant advantages over delaying it until symptoms are more apparent. This has generated much interest and has modified treatment practices in MS. 13, 14 However, some neurologists have questioned the long-term benefit of treating everyone with CIS, suggesting that in some cases the disease will not progress and that greater investigation of patients is warranted before starting more appropriately tailored therapies. 15 Acute idiopathic demyelinating optic neuritis (ON) is a frequent early manifestation of MS that is often indicative of early disease and can be predictive of later progressive stages. 16 Optical coherence tomography (OCT) is an evolving technique that has the potential not only to diagnose ON but also to provide a valuable assessment of MS. 17 This review will consider the evidence for using OCT in patients with ON and its potential role as a tool for routinely monitoring MS.
The Role of Magnetic Resonance Imaging in Multiple Sclerosis
Magnetic resonance imaging (MRI) has revolutionised the diagnosis of MS and greatly facilitated our understanding of MS. Diagnostic criteria based on both clinical and MRI findings have been proposed and have been adopted by many treatment centres. 18 The presence of MRI lesions at symptom onset was found to be correlated with the development of clinically definite MS (CDMS). In patients with one or more T 2 -weighted lesion at baseline, 56% developed MS within 10 years. 19 Neurological damage starts before symptoms become apparent. 
Optic Neuritis in Multiple Sclerosis
The visual system is often affected in MS and, as the retina is an integral part of the central nervous system (CNS), examination of the eye enables unmyelinated axons of the CNS to be visualised directly.
ON is inflammation with accompanying demyelination in the optic nerve that may cause complete or partial loss of vision. It is frequently the initial clinical manifestation of MS and is reported in 94-96% of MS autopsy cases. 21 Although there is a broad age range at onset, most patients with acute demyelinating ON are young (20-45 years of age). 22, 23 There is a gender difference: women are three times as likely as men to develop ON. 22 A patient with typical demyelinating ON usually experiences a decline in vision over a seven-to 10-day period, often characterised by a decline in contrast sensitivity. 24 The progression of visual loss beyond two weeks is distinctly unusual and visual acuity usually recovers well.
In the Optic Neuritis Treatment Trial (ONTT), 25 bands in the CSF is also an independent risk factor for MS. 27 Subclinical or chronic forms of demyelinating ON in which the patient notices a gradual decline in vision instead of acute vision loss followed by improvement may also develop in MS. These patients may show abnormalities on neuro-ophthalmological examination, including field loss, pupillary abnormalities and disc pallor. 28 Subclinical ON can be sensitively detected using lower-contrast letter acuity testing. 29 ON and other visual defects contribute significantly to the reduction in quality of life of MS patients. 30 In patients with acute ON, treatment with a three-day course of highdose (1g/day) intravenous corticosteroids is usually recommended. The
ONTT used three treatment groups: intravenous methylprednisolone for three days followed by an oral prednisone taper; oral prednisone; and oral placebo. 31 The use of oral corticosteroids was associated with an increased risk of recurrent ON five years after an initial bout of ON;
patients who received oral prednisone (1mg/kg) had the highest rate of recurrence (41%) compared with those who received methylprednisolone or placebo (25% for both groups). However, there was no significant difference in the long-term risk of MS.
Optical Coherence Tomography
One of the most exciting developments in ophthalmic imaging is arguably OCT, which was introduced in 1991 32 and has been a part of clinical practice since 1995. 33 OCT is widely used to obtain highresolution images of the retina and the anterior segment of the eye. volume with micron-scale resolution (see Figure 3) . 35, 36 The latest technical improvements, such as higher resolution (between 2 and 3µm) and dual laser beams to overcome eye movements, have enabled these instruments to gain a high clinical utility in predicting MS disease course and determining treatment response.
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Optical Coherence Tomography Studies in Optic Neuritis and Multiple Sclerosis
Among patients with ON, optic nerve atrophy has often been detected by MRI. [38] [39] [40] In a study in the UK including 10 patients with a history of ON, a correlation was found between the mean loss of The arrows delineate the retinal nerve fibre layer. Source: Monteiro et al., 2004. 35 well with RNFL thickness in patients with MS: every one-line decrease in low-contrast letter acuity and contrast sensitivity test score was associated with an average 4µm thinning of the RNFL. 44 Some correlations have been shown between RNLF thickness and disease characteristics. In one study RRMS patients who experienced relapses or a disability progression had a significantly thinner average RNLF compared with patients who remained relapse-free over a two-year period. 45 Lower average RNFL thickness was correlated with patients with more active disease and greater Expanded Disability Status Scale (EDSS) at baseline and greater increase of EDSS over two years. The correlations are better in the temporal quadrant. 46 Correlations have also been found between RNFL thickness and performance on some tests of cognitive function in MS patients, particularly the symbol digit modality test. 45 Despite some conflicting results, longitudinal studies have shown a progressive thinning of RNLF thickness over time, with lower values in progressive MS than in RRMS. 47 In patients with CIS who had no history of ON, our group in Lille failed to find significant differences in RNLF thickness, and changes did not increase the risk of conversion to MS after a sixmonth period of follow-up. 48 However, our analysis was not performed using the latest technical methods. Since RNLF thickness may be associated with the degenerative component of MS, OCT measurements and atrophy of the brain, assessed using the brain parenchymal fraction (BPF), were compared. This identified a partial but significant correlation between BPF and minimum RNLF thickness, and the correlation was stronger in RRMS than in PPMS patients. 49, 50 Determination of axonal thickness in the retina by OCT can therefore provide concurrent information about MRI brain abnormality in MS.
The reliability of OCT in MS was demonstrated in a study in the US. A total of 396 patients with MS and 153 healthy controls were assessed using OCT at three different medical centres; the results showed excellent inter-and intra-rater reproducibility (intra-class correlation
[ICC] 0.89 and 0.98, respectively). 51 In addition, there was excellent inter-visit correlation (ICC 0.91). These results indicated that OCT can be reliably performed at different centres to assess MS patients and can be performed by different operators at different times, with the results remaining comparable.
The feasibility of using OCT as an alternative to MRI scanning for monitoring the effects of glatiramer acetate versus placebo treatment on the condition of the optic nerve is being assessed in a study in The
Netherlands. 52 This study will involve a target 60 patients with clinically diagnosed MS with or without ON, and will also determine the mean change in RNFL in both eyes and other ophthalmological parameters. Another study is investigating the correlation between cognition and RNFL thickness determined by OCT in a group of 20 patients with MS who are receiving either natalizumab or an active comparator. 53 These small studies may provide additional evidence justifying the use of OCT as a lower-cost alternative for monitoring MS patients in both clinical trials and clinical practice. 
Future Perspectives
